A. Moseley

发表

Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.

J. Radich, B. Wood, S. Meshinchi, 2017, Biopreservation and biobanking.

Abstract S5-06: Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202)

C. Moinpour, J. Unger, L. Fehrenbacher, 2017 .

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).

F. Appelbaum, M. Tallman, D. DeAngelo, 2020, Blood advances.

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

C. Bloomfield, F. Appelbaum, R. Stone, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors

A. Neugut, J. Unger, J. Gralow, 2021 .

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report

Emily A. Stevens, J. Radich, B. Wood, 2020, Biomarker Research.

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

J. Radich, R. Larson, F. Appelbaum, 2020, JCO oncology practice.

The significance of serial measurement of serum anti-native DNA antibodies and complement C3 and C4 components in the management of patients with systemic lupus erythematosus.

W. Buchanan, W. Dick, R. Pumphrey, 1977, Australian and New Zealand journal of medicine.

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia

B. Wood, C. Willman, W. Stock, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203

F. Appelbaum, G. Garcia-Manero, M. Othus, 2021, Leukemia & lymphoma.

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

J. Radich, R. Larson, F. Appelbaum, 2016 .

Complement metabolism in the seronegative arthritides.

K. Whaley, W. Dick, R. Sturrock, 1974, Annals of the rheumatic diseases.

Complement metabolism intheseronegative arthritides

W. Morrow, A. Moseley, W. Mitchell, 1974 .

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

C. Moinpour, J. Unger, L. Fehrenbacher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

J. Radich, S. Meshinchi, D. Stirewalt, 2023, Biomarker Research.

Patient Reported Outcomes and Long-Term Non-Adherence to Aromatase Inhibitors.

A. Neugut, S. Ramsey, J. Unger, 2021, Journal of the National Cancer Institute.

Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105.

A. Neugut, S. Ramsey, J. Unger, 2019, Journal of Clinical Oncology.

Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.

A. Neugut, S. Ramsey, J. Unger, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

C. Moinpour, M. Lacouture, A. Barzi, 2020, Journal of Patient-Reported Outcomes.

Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials

S. Ramsey, R. Osarogiagbon, J. Unger, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Socioeconomic deprivation and cancer outcomes in patients treated in clinical trials.

S. Ramsey, R. Osarogiagbon, J. Unger, 2019, Journal of Clinical Oncology.

Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials

S. Ramsey, J. Unger, M. Chávez-MacGregor, 2018, JAMA network open.

Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib in Ph+ Acute Lymphoblastic Leukemia.

B. Wood, S. O'brien, M. Othus, 2022, Blood advances.

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

M. Liedtke, M. Othus, I. Aldoss, 2019, Blood.

Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia

B. Wood, W. Stock, R. Stone, 2018, Blood.

Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105).

A. Neugut, S. Ramsey, J. Unger, 2020 .

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

J. Radich, M. Othus, A. Im, 2019, Blood.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

J. Forbes, R. Gelber, G. Hortobagyi, 2018, Journal of the National Cancer Institute.

Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials

S. Ramsey, J. Unger, M. Chávez-MacGregor, 2018, Cancer.